Background: Chemotherapy-induced peripheral neuropathy (CIPN) can interfere with daily function and quality of life, and there are no known preventive approaches. In a cohort of breast cancer patients receiving paclitaxel as part of a clinical trial (SWOG 0221), we examined the use of dietary supplements both before diagnosis and during treatment in relation to CIPN. Methods: At registration to S0221, 1225 breast cancer patients completed questionnaires regarding the use of multivitamins and supplements before and at diagnosis. A second questionnaire at six months queried use during treatment. Supplement use was evaluated in relation to CIPN, assessed via the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v. 3.0) and the self-reported Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity (FACT/GOG-Ntx) subscale. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed with logistic regression for the CTCAE analyses and ordinal regression for the FACT/GOG-Ntx analyses. Results: Multivitamin use before diagnosis was associated with reduced symptoms of CIPN (CTCAE-adjusted OR = 0.60, 95% CI = 0.42 to 0.87; FACT/GOG-Ntx-adjusted OR = 0.78, 95% CI = 0.61 to 1.00). Use during treatment was marginally inversely associated with CIPN (CTCAE-adjusted OR = 0.73, 95% CI = 0.49 to 1.08; FACT/GOG-Ntx-adjusted OR = 0.77, 95% CI = 0.60 to 0.99). Other supplement use, either before diagnosis or during treatment, was not statistically significantly associated with CIPN. Conclusions: Multivitamin use may be associated with reduced risk of CIPN, although individual dietary supplement use did not appreciably affect risk. Multivitamin use could be a surrogate for other related behaviors that are the actual drivers of the association with reduced CIPN. Without prospective randomized trials of vitamin supplementation, recommendations for use or changes to clinical practice are clearly not warranted.
Background: Chemotherapy-induced peripheral neuropathy (CIPN) can interfere with daily function and quality of life, and there are no known preventive approaches. In a cohort of breast cancerpatients receiving paclitaxel as part of a clinical trial (SWOG 0221), we examined the use of dietary supplements both before diagnosis and during treatment in relation to CIPN. Methods: At registration to S0221, 1225 breast cancerpatients completed questionnaires regarding the use of multivitamins and supplements before and at diagnosis. A second questionnaire at six months queried use during treatment. Supplement use was evaluated in relation to CIPN, assessed via the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v. 3.0) and the self-reported Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity (FACT/GOG-Ntx) subscale. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed with logistic regression for the CTCAE analyses and ordinal regression for the FACT/GOG-Ntx analyses. Results: Multivitamin use before diagnosis was associated with reduced symptoms of CIPN (CTCAE-adjusted OR = 0.60, 95% CI = 0.42 to 0.87; FACT/GOG-Ntx-adjusted OR = 0.78, 95% CI = 0.61 to 1.00). Use during treatment was marginally inversely associated with CIPN (CTCAE-adjusted OR = 0.73, 95% CI = 0.49 to 1.08; FACT/GOG-Ntx-adjusted OR = 0.77, 95% CI = 0.60 to 0.99). Other supplement use, either before diagnosis or during treatment, was not statistically significantly associated with CIPN. Conclusions: Multivitamin use may be associated with reduced risk of CIPN, although individual dietary supplement use did not appreciably affect risk. Multivitamin use could be a surrogate for other related behaviors that are the actual drivers of the association with reduced CIPN. Without prospective randomized trials of vitamin supplementation, recommendations for use or changes to clinical practice are clearly not warranted.
Authors: S E Jones; J Erban; B Overmoyer; G T Budd; L Hutchins; E Lower; L Laufman; S Sundaram; W J Urba; K I Pritchard; R Mennel; D Richards; S Olsen; M L Meyers; P M Ravdin Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: J M Nabholtz; K Gelmon; M Bontenbal; M Spielmann; G Catimel; P Conte; U Klaassen; M Namer; J Bonneterre; P Fumoleau; B Winograd Journal: J Clin Oncol Date: 1996-06 Impact factor: 44.544
Authors: Luis J Leandro-García; Susanna Leskelä; Carlos Jara; Henrik Gréen; Elisabeth Avall-Lundqvist; Heather E Wheeler; M Eileen Dolan; Lucia Inglada-Perez; Agnieszka Maliszewska; Aguirre A de Cubas; Iñaki Comino-Méndez; Veronika Mancikova; Alberto Cascón; Mercedes Robledo; Cristina Rodríguez-Antona Journal: Clin Cancer Res Date: 2012-06-20 Impact factor: 12.531
Authors: George T Budd; William E Barlow; Halle C F Moore; Timothy J Hobday; James A Stewart; Claudine Isaacs; Muhammad Salim; Jonathan K Cho; Kristine J Rinn; Kathy S Albain; Helen K Chew; Gary V Burton; Timothy D Moore; Gordan Srkalovic; Bradley A McGregor; Lawrence E Flaherty; Robert B Livingston; Danika L Lew; Julie R Gralow; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2014-11-24 Impact factor: 44.544
Authors: R Michael Baldwin; Kouros Owzar; Hitoshi Zembutsu; Aparna Chhibber; Michiaki Kubo; Chen Jiang; Dorothy Watson; Rachel J Eclov; Joel Mefford; Howard L McLeod; Paula N Friedman; Clifford A Hudis; Eric P Winer; Eric M Jorgenson; John S Witte; Lawrence N Shulman; Yusuke Nakamura; Mark J Ratain; Deanna L Kroetz Journal: Clin Cancer Res Date: 2012-07-27 Impact factor: 12.531
Authors: Jean E Abraham; Qi Guo; Leila Dorling; Jonathan Tyrer; Susan Ingle; Richard Hardy; Anne-Laure Vallier; Louise Hiller; Russell Burns; Linda Jones; Sarah J Bowden; Janet A Dunn; Christopher J Poole; Carlos Caldas; Paul P D Pharoah; Helena M Earl Journal: Clin Cancer Res Date: 2014-03-05 Impact factor: 12.531
Authors: Heather Greenlee; Dawn L Hershman; Zaixing Shi; Marilyn L Kwan; Isaac J Ergas; Janise M Roh; Lawrence H Kushi Journal: J Natl Cancer Inst Date: 2016-10-28 Impact factor: 11.816
Authors: Gary R Zirpoli; Patrick M Brennan; Chi-Chen Hong; Susan E McCann; Gregory Ciupak; Warren Davis; Joseph M Unger; G Thomas Budd; Dawn L Hershman; Halle C F Moore; James Stewart; Claudine Isaacs; Timothy Hobday; Muhammad Salim; Gabriel N Hortobagyi; Julie R Gralow; Kathy S Albain; Christine B Ambrosone Journal: Breast Cancer Res Treat Date: 2013-01-10 Impact factor: 4.872
Authors: Christine B Ambrosone; Gary R Zirpoli; Alan D Hutson; William E McCann; Susan E McCann; William E Barlow; Kara M Kelly; Rikki Cannioto; Lara E Sucheston-Campbell; Dawn L Hershman; Joseph M Unger; Halle C F Moore; James A Stewart; Claudine Isaacs; Timothy J Hobday; Muhammad Salim; Gabriel N Hortobagyi; Julie R Gralow; George T Budd; Kathy S Albain Journal: J Clin Oncol Date: 2019-12-19 Impact factor: 44.544
Authors: Yihan Sun; Jae Hyun Kim; Kiran Vangipuram; Daniel F Hayes; Ellen M L Smith; Larisa Yeomans; N Lynn Henry; Kathleen A Stringer; Daniel L Hertz Journal: Breast Cancer Res Treat Date: 2018-06-26 Impact factor: 4.872
Authors: Katie Watts; Christopher Wills; Ayman Madi; Claire Palles; Timothy S Maughan; Richard Kaplan; Nada A Al-Tassan; Rachel Kerr; David J Kerr; Richard S Houlston; Valentina Escott-Price; Jeremy P Cheadle Journal: Int J Cancer Date: 2022-05-10 Impact factor: 7.316
Authors: Jennifer M Mongiovi; Gary R Zirpoli; Rikki Cannioto; Lara E Sucheston-Campbell; Dawn L Hershman; Joseph M Unger; Halle C F Moore; James A Stewart; Claudine Isaacs; Timothy J Hobday; Muhammad Salim; Gabriel N Hortobagyi; Julie R Gralow; G Thomas Budd; Kathy S Albain; Christine B Ambrosone; Susan E McCann Journal: Breast Cancer Res Date: 2018-11-28 Impact factor: 6.466